[PDF] Top 20 Diseño de plan de marketing digital. Caso práctico: Hotel Villaflor.
Has 10000 "Diseño de plan de marketing digital. Caso práctico: Hotel Villaflor." found on our website. Below are the top 20 most common "Diseño de plan de marketing digital. Caso práctico: Hotel Villaflor.".
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
... the alemtuzumab- treated patients, with improvements in all 7 EDSS functional domains, suggest that such disabilities may often be reversible (at least partially) in patients with active RRMS ... See full document
8
Alemtuzumab in the treatment of multiple sclerosis
... Twenty-seven patients in varying stages of disease were enrolled and assessed before and 18 months after a single pulse of ...in patients with less cerebral inflammation in the pretreatment ...progressive ... See full document
8
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
... RRMS patients treated for two years with once weekly intramuscular interferon beta (IFNβ) in the MSCRG phase III trial showed significantly less GM atrophy compared with placebo, during year two after treatment ... See full document
10
Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
... intravenous alemtuzumab and were followed up for a mean of 29 months; most received methylprednisolone pretreat- ment to ameliorate the associated cytokine release syndrome and 19 (86%) agreed to a second 3-day ... See full document
8
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
... Abstract: Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms ... See full document
8
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
... arm. Alemtuzumab has demonstrated impressive efficacy when compared with subcutaneous interferon b -1a in three clinical ...for patients with highly active ...adult patients with ... See full document
46
Whole Brain N Acetylaspartate Concentration: Correlation with T2 Weighted Lesion Volume and Expanded Disability Status Scale Score in Cases of Relapsing Remitting Multiple Sclerosis
... For the present study, we correlated whole-brain NAA levels with T2-weighted lesion volumes and EDSS scores in a cohort of patients with relapsing- remitting multiple sclerosis. Whole-brain NAA ... See full document
100
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
... (pre) B cells with ATL1102 treatment suggests that release of lymphoid precursors into the blood may be low or they do not survive, potentially reducing the pool of cells that may carry latent virus. ATL1102 does not ... See full document
7
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
... randomized patients who are administered PEG-IFN beta-1a at a dose of 125 µ g every 2 weeks or 4 weeks after an initial titration phase starting at 63 µ ...involve patients aged 18–65 years suffering from ... See full document
66
Migraine-Like Headache and Status Migrainosus as Attacks of Multiple Sclerosis in a Child
... nating lesions in the red nucleus, sub- stantia nigra, and PAG matter are re- sponsible for the presence of migraine in patients with MS. Therefore, the brainstem nuclei, particularly those in the midbrain, ... See full document
17
Deciphering the role of DNA methylation in multiple sclerosis: emerging issues
... of MS [50] and could provide us more information regarding a possible clinical application of DNA methy- lation as MS ...in patients with MS would provide physicians with a clinically useful ... See full document
74
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon gamma and is defective in chronic progressive multiple sclerosis
... in patients with chronic progressive multiple sclerosis (MS) as compared to patients with relapsing- remitting MS or normal ... See full document
178
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
... % patients developed relevant medical side-effects (injection associated unremitting chest pain, allergic reactions or severe local reactions such as marked ...treatment-naive patients, and this was ... See full document
36
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... pipeline to 2D images, given their availability in this retrospective study and our previous demonstration that these images showed 1) sensitivity to disease-specific ef- fects and 2) high reproducibility [29]. We did ... See full document
11
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
... Expanded Disability Status Scale [EDSS] score) and patient-reported outcome (PRO) measures ...RRMS, patients have reported reductions in their quality of life and ability to work [8], suggesting a need for ... See full document
23
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis
... in patients on IFNβ therapy is well established ...addition, patients were re- quired to complete 1–4 years of therapy before study entry, the time frame of greatest importance in NAb ... See full document
25
BG-12 and its potential for the prevention of relapse in multiple sclerosis
... In two major Phase III trials, BG-12 has now produced a consistent effect both reducing the frequency of relapses in RRMS subjects, and reducing new T 2 and Gd-enhancing MRI lesions. These effects are consistent with its ... See full document
12
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
... for patients with relapsing-remitting (RR) MS who experienced relapses with disability progression (Expanded Disability Status Scale [EDSS] ...on MS disease-modifying ... See full document
10
Nuclear factor erythroid 2 related factor 2 is a critical target for the treatment of glucocorticoid resistant lupus nephritis
... In conclusion, Nrf2 activators had not only anti- inflammatory effects but also organ-protective effects on LN pathology. In other words, targeted Nrf2 drugs may be more effective than the currently used immunosuppres- ... See full document
10
Magnetization Transfer Ratio Histogram Analysis of Gray Matter in Relapsing remitting Multiple Sclerosis
... of MS pa- ...among patients may suggest that low peak height would then tend to indicate more disease process in gray matter and therefore higher EDSS (Fig ...and disability noted in previous studies ... See full document
157
Related subjects